Parkinson's Disease Neuroprotection Clinical Trial

帕金森病神经保护临床试验

• 批准号: 6544965
• 负责人: GEORGE F WOOTEN
• 金额: $ 10.88万
• 依托单位: UNIVERSITY OF VIRGINIA
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-09-30 至 2007-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6544965
• 关键词: Parkinson's disease; chemoprevention; clinical research; cooperative study; human subject; human therapy evaluation; medical outreach /case finding; nervous system disorder chemotherapy; neuroprotectants; patient oriented research

DESCRIPTION (provided by applicant): This is an application for a Clinical Center for the Parkinson's Disease Neuroprotection Trial from the Department of Neurology at the University of Virginia in response to RFA-NS-02-010. We have a clinical staff of four movement disorder subspeciality neurologists, a nurse coordinator, an administrative coordinator, and an information and referral coordinator. Over the past 10 years, our team has enrolled 445 subjects in clinical trials with 413 subjects completing the protocol. Our diagnostic accuracy and interrater reliability are documented objectively and are excellent. We have been highly productive of scholarly publications with 26-refereed publications on clinical aspects of PD in the past 5 years. Over the past six years we have ascertained 150 patients with a clinical diagnosis of Parkinson's disease (PD) who were receiving no symptomatic therapy. We have excellent alliances with multiple patient support groups and both referring neurologists and primary care physicians throughout the state of Virginia. Our team is experienced, productive, and fully able to meet the requirements to become a Clinical Cente for the Parkinson's Disease Neuroprotection Trial.

描述（由申请人提供）：这是弗吉尼亚大学神经病学系帕金森氏病神经保护试验临床中心的申请，以响应RFA-NS-02-010。我们有四个运动障碍的临床人员，外科神经病学家，护士协调员，行政协调员以及信息和推荐协调员。在过去的10年中，我们的团队已招募445名受试者参加临床试验，其中413名受试者完成了该协议。我们的诊断准确性和互置可靠性被客观地记录在客观上，并且非常出色。在过去的5年中，我们拥有有关PD临床方面的26条出版物的学术出版物的高度生产力。在过去的六年中，我们确定了150名患有未接受症状治疗的帕金森氏病（PD）的患者。我们与多个患者支持小组以及整个弗吉尼亚州的神经科医生和初级保健医生都有了良好的联盟。我们的团队经验丰富，富有成效，并且能够满足成为帕金森氏病神经保护试验的临床百分比的要求。